SGMO Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of -95.02%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.81, signalling upside risk potential of 611.95%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $33.56 which suggests that it could grow by 349.2%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.114% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.17%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.04x versus 2.38x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of -2301.55%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Sangamo Therapeutics, Inc. has a consensus price target of $3.81, signalling upside risk potential of 611.95%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 79.11%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.114% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.04x versus 55.57x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of -12425.36%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.81, signalling upside risk potential of 611.95%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.2500 which suggests that it could grow by 223.22%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.114% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.04x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of 13.19%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.81, signalling upside risk potential of 611.95%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 370.09%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.291, which suggesting that the stock is 29.114% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 33.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.04x versus 2.98x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.